Friday, March 11, 2011

Ganetespib well tolerated with favorable safety profile in over 350 patients treated to date

Synta Announces Clinical Program Updates and 2010 Financial Results. Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported fourth-quarter and full-year 2010 financial results, provided an update on recent progress with its programs, and announced 2011 objectives.

read story
www.businesswire.com/news/home/20110311005403/en/Synta-Announces-Clinical-Program-Updates-2010-Financial

No comments:

Post a Comment